Whilst standard therapeutic doses of semaglutide or liraglutide are carefully calibrated through extensive clinical trials, microdosing involves using a fraction of these established dosesoften below licensed starting doses
Studies have shown that patients taking semaglutide GLP-1 lost more weight than those on a placebo, and had a greater reduction in body fat
Lotte Bjerre Knudsen (07:15): Yeah, it was a stepwise process
Secondly, GLP-1 receptor agonists carry important safety considerations including risk of pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (based on rodent studies, though human relevance remains uncertain)
For short-acting agents like exenatide immediate-release (Byetta) and lixisenatide (Adlyxin), timing is specifically linked to mealsthese must be administered within 60 minutes before eating
Please talk with your doctor about the risks and side effects before starting any GLP-1 medication